TG Therapeutics Q2 BRIUMVI Revenue Hits $228M, Raises 2026 Guidance to ~$950M
TGTX has more than doubled off its 52-week low of $25.28.
Summary
TG Therapeutics delivered Q2 BRIUMVI U.S. revenue of $228M, a 64% jump year-over-year, and lifted its full-year 2026 total revenue guidance to approximately $950M — above the $885M–$900M range set in May. The beat and raise signal accelerating commercial traction for its lead multiple sclerosis drug. This follows the May guidance hike and positive Phase 3 ENHANCE data, reinforcing the growth narrative. With a $7.96B market cap, the raised outlook materially shifts the revenue trajectory. Next catalyst: potential subcutaneous BRIUMVI data readouts later this year.
At the time of this announcement, TGTX was trading at $51.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8B. The 52-week trading range was $25.28 to $59.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.